(EHC) Encompass Health - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29261A1007
EHC: Rehabilitation, Hospitals, Healthcare, Therapy, Nursing, Medical
Encompass Health Corporation stands as a pivotal player in the post-acute care sector, specializing in rehabilitation services that bridge the gap between acute care and recovery. Their focus on inpatient rehabilitation hospitals underscores their commitment to addressing the complex needs of patients recovering from severe injuries or debilitating conditions such as strokes and hip fractures. This strategic positioning within the healthcare continuum highlights their role in optimizing patient outcomes and reducing healthcare costs through specialized care.
The companys operational model is rooted in a network of inpatient rehabilitation hospitals, where a multidisciplinary team of medical professionals, including physicians, nurses, and therapists, collaborates to provide comprehensive care. This integrated approach not only enhances patient recovery but also aligns with broader industry trends towards value-based care and cost-effective treatment solutions. Encompass Healths scale and operational efficiency are notable, allowing them to maintain a strong presence across the U.S. and Puerto Rico.
From a financial perspective, Encompass Health presents an intriguing profile for investors. With a market capitalization exceeding $10 billion, the company demonstrates substantial scale. The trailing P/E ratio of 22.31 and forward P/E of 20.58 suggest a valuation that reflects both current performance and future growth expectations. The price-to-book ratio of 4.88 indicates a premium on book value, potentially signaling confidence in the companys intangible assets and growth prospects. The price-to-sales ratio of 1.89 further highlights reasonable valuation relative to revenue.
Originally known as HealthSouth Corporation, the company rebranded as Encompass Health in 2018, a move that may signal a strategic shift towards a more holistic approach to healthcare. This rebranding could reflect an expansion of services or a change in corporate strategy, aligning with evolving industry dynamics. Incorporated in 1984 and headquartered in Birmingham, Alabama, Encompass Health
Additional Sources for EHC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EHC Stock Overview
Market Cap in USD | 10,162m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 1986-09-30 |
EHC Stock Ratings
Growth 5y | 38.7% |
Fundamental | 55.0% |
Dividend | 13.3% |
Rel. Strength Industry | 28.9 |
Analysts | 4.85/5 |
Fair Price Momentum | 91.95 USD |
Fair Price DCF | 34.29 USD |
EHC Dividends
Dividend Yield 12m | 0.68% |
Yield on Cost 5y | 0.86% |
Annual Growth 5y | -12.01% |
Payout Consistency | 93.1% |
EHC Growth Ratios
Growth Correlation 3m | -17.1% |
Growth Correlation 12m | 90.9% |
Growth Correlation 5y | 34.1% |
CAGR 5y | 5.43% |
CAGR/Max DD 5y | 0.11 |
Sharpe Ratio 12m | 1.23 |
Alpha | 18.69 |
Beta | 0.61 |
Volatility | 22.13% |
Current Volume | 791.5k |
Average Volume 20d | 745.5k |
As of February 22, 2025, the stock is trading at USD 97.53 with a total of 791,510 shares traded.
Over the past week, the price has changed by -3.30%, over one month by +1.82%, over three months by -1.70% and over the past year by +31.82%.
Partly, yes. Based on ValueRay Fundamental Analyses, Encompass Health (NYSE:EHC) is currently (February 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 55.00 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EHC as of February 2025 is 91.95. This means that EHC is currently overvalued and has a potential downside of -5.72%.
Encompass Health has received a consensus analysts rating of 4.85. Therefor, it is recommend to buy EHC.
- Strong Buy: 11
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, EHC Encompass Health will be worth about 105.3 in February 2026. The stock is currently trading at 97.53. This means that the stock has a potential upside of +7.92%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 117.3 | 20.2% |
Analysts Target Price | 116.5 | 19.5% |
ValueRay Target Price | 105.3 | 7.9% |